Study Finds No Difference Between Avastin and Lucentis in Treatment of AMD
October 8, 2010
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System recently announced the results of a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing Avastin and Lucentis. Last October, these same researchers published early, six month outcomes of the same study, which also failed to show a difference in efficacy between these two drugs for treating AMD.
Read the full press release here.
For interested readers, Irv Arons is keeping track of the results of Avastin vs. Lucentis studies on his blog.
Jump down to form below to submit your own comments